Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Well deserved recognition for @ProfSharonLewin picking up the top gong from @Committee4Melb A virologist and director, we collectively looked to Sharon for advice on Melbourne's response to the pandemic. An incredible response from a remarkable leader https://twitter.com/WISparkville/status/1330770627829977088

WISPP@WISparkville

Congratulations ⁦@ProfSharonLewin⁩ ! https://www.theage.com.au/politics/victoria/doherty-chief-awarded-top-gong-says-pandemic-has-changed-the-way-victorians-work-20201123-p56gzl.html

New low budget PR video from the power saddle @MonashBDI Recent @jlb_journal article from now @oNKo_innate crew on primary human NK cell editing with #CRISPR RNP. No @OceanSprayInc cranberry but the fine folk @iamspecialized have provided the S-Works SL7 ride #innovation #nkcell https://twitter.com/jlb_journal/status/1321169050026889216

Journal of Leukocyte Biology@jlb_journal

Another great #NK paper this month in #JLB! In this issue, @Dr_Nick_Bikes discusses the use of CRISPR RNP for drug target validation in primary human NK cells in #Cancer #Immunotherapy. Check it out - https://buff.ly/2GCMvFm

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are